The short version of GLP-1 analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-04. Anything still debated is marked as such rather than presented as settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
=== Recombinant functionality === Novel recombinant technologies have made it possible to improve fusion protein design for use in fields as diverse as biodetection, paper and food industries, and biopharmaceuticals. Recent improvements have involved the fusion of single peptides or protein fragments to regions of existing proteins, such as N and C termini, and are known to increase the following properties:
=== Top-down methods === Top-down methods adopt some 'force' (e. g. mechanical force, laser) to break bulk materials into nanoparticles. A popular method involves mechanical break apart bulk materials into nanomaterials is 'ball milling'. Besides that, nanoparticles can also be made by laser ablation which apply short pulse lasers (e. g. femtosecond laser) to ablate a target (solid).
== Role in oligonucleotide formation == Phosphorimidazolides have been investigated for their mechanistic role in abiogenesis (the natural process by which life arose from non-living matter). Specifically, they have been proposed as the active electrophilic species which may have mediated the formation of inter-nucleotide phosphodiester bonds, thereby enabling template-directed oligonucleotide replication before the advent of enzymes. Phosphorimidazolides were originally proposed as mediators of this process by Leslie Orgel in 1968. Early studies showed that divalent metal cations such as Mg2+, Zn2+, and Pb2+ and a complementary template were required for the formation of short oligonucleotides, although nucleotides exhibited 5'-2' connectivity instead of 5'-3' connectivity of present-day life forms. It was also shown that Montmorillonite clay could provide a surface for phosphorimidazolide-mediated oligonucleotide formation with lengths of 20-50 bases. The research group of Jack W. Szostak has continued to investigate the role of phosphorimidazolides in pre-biotic nucleotide polymerization. The group has investigated a number of imidazole derivatives in the search for chemical moieties which provide longer oligonucleotides necessary for propagating genetic information. Significantly, they discovered that phosphorimidazolides promote template-directed oligonucleotide formation via imidazolium-bridged dinucleotide intermediates. John D.
TGF-β is a cytokine that plays a critical role in the regulation of extracellular matrix (ECM) production and cellular differentiation. It is a potent stimulator of fibrosis, and increased TGF-β signaling is associated with the development of fibrosis in various organs. CTGF is a matricellular protein involved in ECM production and remodeling. It is up-regulated in response to TGF-β and has been implicated in the development of pulmonary fibrosis. EGFR is a transmembrane receptor that plays a role in cellular proliferation, differentiation, and survival. Dysregulated EGFR signaling has been implicated in the development of pulmonary fibrosis, and drugs that target EGFR have been shown to have therapeutic potential in the treatment of the disease. IL-13 is a cytokine involved in regulating immune responses. It has been shown to promote fibrosis in the lungs by stimulating the production of ECM proteins and the recruitment of fibroblasts to sites of tissue injury. PDGF is a cytokine that plays a key role in the regulation of cell proliferation and migration. It is involved in the recruitment of fibroblasts to sites of tissue injury in the lungs, and increased PDGF signaling is associated with the development and progression of pulmonary fibrosis. Wnt/β-catenin signaling plays a critical role in tissue repair and regeneration, and dysregulated Wnt/β-catenin signaling has been implicated in the development of pulmonary fibrosis.
== Other animals == Rhabdomyolysis is recognized in horses. Horses can develop several muscle disorders, many of which may progress to rhabdomyolysis. Of these, some cause isolated attacks of rhabdomyolysis (e.g., dietary deficiency in vitamin E and selenium, poisoning associated with pasture or agricultural poisons such as organophosphates), while others predispose to exertional rhabdomyolysis (e.g., the hereditary condition equine polysaccharide storage myopathy). Of thoroughbred horses, 5–10% and some standardbred horses have the condition equine exertional rhabdomyolysis; no specific cause has been identified, but an underlying muscle calcium regulation disorder is suspected. Rhabdomyolysis affecting horses may also occur in outbreaks; these have been reported in many European countries, and later in Canada, Australia, and the United States. It has been referred to as "atypical myopathy" or "myoglobinuria of unknown etiology". No single cause has yet been found, but various mechanisms have been proposed, and a seasonal pattern has been observed. Very high creatine kinase levels are detected, and mortality from this condition is 89%.
Sources: en.wikipedia.org
== Research == PPAR-gamma agonists have been used in the treatment of hyperlipidaemia and hyperglycemia. Many insulin sensitizing drugs (namely, the thiazolidinediones) used in the treatment of diabetes activate PPARG as a means to lower serum glucose without increasing pancreatic insulin secretion. Activation of PPARG is more effective for skeletal muscle insulin resistance than for insulin resistance of the liver.
=== Hydrogen storage === Graphene oxide is also being explored for its applications in hydrogen storage. Hydrogen molecules can be stored among the oxygen-based functional groups found throughout the sheet. This hydrogen storage capability can be further manipulated by modulating the interlayer distance between sheets, as well as making changes to the pore sizes. Research in transition metal decoration on carbon sorbents to enhance hydrogen binding energy has led to experiments with titanium and magnesium anchored to hydroxyl groups, allowing for the binding of multiple hydrogen molecules.
Thus an antigen might bind specifically to a T or B cell receptor, but not induce an adaptive immune response. If the antigen does induce a response, it is an 'immunogenic antigen', which is referred to as an immunogen.
Bektashis believe in God and follow all Islamic prophets. Bektashis claim the heritage of Haji Bektash Veli, who was a descendant of Ali, Husayn ibn Ali, Ali al-Sajjad and other Imams. In contrast to many Twelver Shia, Bektashis respect all companions of Muhammad, including Abu Bakr, Umar, Uthman, Talha, Mu'awiya, and Ali who is considered the greatest of them. Bektashis follow the teachings of Haji Bektash, who preached about the Twelve Imams. Bektashis differ from other Muslims by also following the Fourteen Innocents, who either died in infancy or were martyred with Husayn. Abbas ibn Ali is also an important figure in Bektashism, and Bektashis visit Mount Tomorr to honor him in an annual pilgrimage to the Abbas Ali Türbe on August 20–25. In addition to the Muslim five daily prayers, Bektashis have two specific prayers, one at dawn and another at dusk for the welfare of all humanity. Bektashism places much emphasis on the concept of Wahdat al-Wujud (Arabic: وحدة الوجود, romanized: Unity of Being) that was formulated by Ibn Arabi. Malakat is an important Bektashi text, perhaps written by Haji Bektash. Some scholars question whether the Malakat was actually authored by Haji Bektash. Resultingly, those scholars question whether the presentation of Haji Bektash and Bektashism as orthoprax in Islam (practicing orthodox Islam). There remains dispute as to whether Bektashis have historically followed the shariah law of Islam.
=== Timeline of the struggle for professional equality in France === 1900: Law allowing women full access to the bar, including the right to plead. 1907: A law authorizes married women to freely dispose of their salary. Previously, all earnings went to their husbands. They are also now allowed to sit on labor tribunals. 1908: Law grants eight weeks of maternity leave, unpaid. 1920: Women can join a union without their husband's authorization. 1924: Women are allowed to take the baccalauréat exam (some had already done so in the past, notably Julie-Victoire Daubié, but from now on, secondary education is the same for both sexes, allowing more girls to aim for this diploma). 1928: Two-month fully paid maternity leave is granted in the civil service. 1938: Women's legal incapacity is lifted. They can attend university, pursue studies, and obtain an identity card or passport without their husband's permission (Renoult law). However, the husband remains the head of the household and can forbid his wife from working. 1942: Widowed women are allowed to work, even if their husbands were employed, provided this does not cause layoffs. 1944: Women are granted the right to vote. 1945: The concept of "women's wages" is abolished. The principle "equal pay for equal work" is written into the legislation. 1946: Women can become judges. 1965: Reform of matrimonial regimes: women can work and open a bank account without their husband's authorization and benefit from social advantages. 1967: Medical contraception is legalized by the Neuwirth law.
Sources: en.wikipedia.org
=== 2. Periodontal ligament === The periodontal ligament is a specialized, vascular, and cellular connective tissue occupying the space between the cementum of the tooth root and the alveolar bone socket. It is primarily composed of dense collagen fiber bundles, known as Sharpey's fibers, which anchor the tooth to the surrounding alveolar bone. Functionally, the periodontal ligament acts as a shock absorber during mastication, provides proprioceptive sensory input, and contributes to the nutritional and reparative capacity of the periodontal tissues. In periodontitis, progressive destruction of periodontal ligament fibers occurs in association with apical migration of the junctional epithelium, resulting in increased tooth mobility.
In 1949, its genetic transmission was determined by E. A. Beet and J. V. Neel. In 1954, it was established that carriers of the abnormal gene are protected to some degree against malaria, which accounts for its persistence in populations threatened by malaria.
=== Protein per calorie === Protein content in foods is often measured in protein per serving rather than protein per calorie. For instance, the USDA lists 6 grams of protein per large whole egg (a 50-gram serving) rather than 84 mg of protein per calorie (71 calories total). For comparison, there are 2.8 grams of protein in a serving of raw broccoli (100 grams) or 82 mg of protein per calorie (34 calories total), or the Daily Value of 47.67g of protein after eating 1,690g of raw broccoli a day at 574 cal. An egg contains 12.5g of protein per 100g, but 4 mg more protein per calorie, or the protein DV after 381g of egg, which is 545 cal. The ratio of essential amino acids (the quality of protein) is not taken into account, one would actually need to eat more than 3 kg of broccoli a day to have a healthy protein profile, and almost 6 kg to get enough calories. It is recommended that adult humans obtain between 10–35% of their 2000 calories a day as protein.
== Education == Anoop Jacob has a degree from Kerala Law Academy Law College, Thiruvananthapuram and is a practising lawyer at the Kerala High Court. Prior to that he completed his bachelor's in English Literature from Mar Ivanios College, Thiruvananthapuram.
=== Biosynthesis === Similar to other pheromone biosynthesis reactions, female cabbage looper pheromone production initiates with synthesis of 16 and 18-carbon fatty acids. This is followed by desaturation at C1 and chain shortening by two or four carbons. Finally, the fatty acid is reduced and acetylated to form an acetate ester. The result is a blend of different female pheromone compounds at a consistent ratio. This ratio can be highly altered by mutations in chain shortening proteins, demonstrating that the chain shortening step is important for determining the ratio of pheromones in the final blend. As a species, the cabbage looper does not hormonally regulate pheromone production. Stage specific proteins correspond to the development of the pheromone gland. The immature gland lacks numerous enzymes crucial to pheromone biosynthesis, such as fatty acid synthetase and acetyltransferase, which is why the looper cannot produce pheromones prior to the adult stage. Upon complete development of the pheromone glands at the adult stage, pheromones are constantly produced.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.